ArticleDiscover oncology2025
No significant link found between Helicobacter pylori serological antibodies and the development of esophageal adenocarcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundPrevious observational studies have suggested a protective effect of Helicobacter pylori (HP) infection against the incidence of esophageal adenocarcinoma(EAC). To further validate this perspective at the genetic level, we employed Mendelian randomization (MR) to analyze the correlation between HP infection-related serological antibodies and EAC in the European population.
methodsThis study employed a two-sample MR analysis method, utilizing GWAS data on seven serological antibodies related to HP infection selected from European populations as instrumental variables. The outcome data comprised GWAS data from 16,790 cases of EAC. Three analytical techniques were employed: inverse variance weighting, Egger -MR, and weighted median method. Additionally, Cochran's Q test, Egger -MR intercept test, MR-Presso method, and leave-one-out analysis were utilized for sensitivity analyses.
resultsThe results of analysis indicated no clear relationship between the seven serological antibodies related to HP infection and the incidence of EAC in European populations(all p > 0.05). The secondary outcomes further validated the previously mentioned results (p > 0.05), with analyses of heterogeneity (p > 0.05) and pleiotropy (p > 0.05) confirming the robustness of the MR results.
conclusionNo significant association was detected between various serological antibodies related to HP infection and the incidence of EAC in the European population. This may, to some extent, negated the protective role of HP infection against EAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.